Novo Nordisk hits $500bn market value, climbing closer to the $1tn club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this yearBy Press Room31 January 2024 Novo Nordisk has shown few signs of slowing down since taking the pharmaceutical world by storm last year. Now, the…
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030By Press Room27 January 2024 North Carolina is cutting off coverage of anti-obesity medications for state employees, citing soaring costs and a lack of agreement…
Little-Known Biotech Company Shows How Hard It Is To Ride The Ozempic WaveBy Press Room22 January 2024 Shares of Korea-listed Caregen surged on hope its diabetes-weight loss supplement could give the little-known biotech company an Ozempic-like boost.…
Passage Of Treat And Reduce Obesity Act Faces An Uphill BattleBy Press Room4 January 2024 A push to lift Medicare’s prohibition on coverage of weight loss drugs is picking up steam in Congress. The history…